Patriot Financial Group Insurance Agency LLC Buys 2,887 Shares of Becton, Dickinson and Company $BDX

Patriot Financial Group Insurance Agency LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 25.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,301 shares of the medical instruments supplier’s stock after purchasing an additional 2,887 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Becton, Dickinson and Company were worth $2,463,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $27,000. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $31,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $191.43 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market capitalization of $54.87 billion, a P/E ratio of 34.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. The company’s 50-day moving average is $188.87 and its 200 day moving average is $187.95. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Piper Sandler restated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus upped their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price objective on the stock. Finally, Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.